FIELD: medicine.
SUBSTANCE: invention refers to biochemistry, particularly to affinity-matured CRIg versions. Declared is the CRIg versions, which is an alternative complement pathway inhibitor at least twice stronger than human CRIg with a native sequence, and optionally possesses C3b-bindingaffinity at least twice as much. There are also declared a chimeric molecule and a pharmaceutical composition, both containing the above CRIg version. The CRIg version can be used for preparing a therapeutic agent for treating a complement-associated disease or condition.
EFFECT: invention enables improving the therapeutic effectiveness of CRIg polypeptides.
17 cl, 17 dwg, 4 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| C3b ANTIBODIES AND METHODS FOR PREVENTION AND TREATMENT OF COMPLEMENT-RELATED DISORDERS | 2008 |
|
RU2473563C2 |
| POLYPEPTIDE VARIANTS WITH CHANGED EFFECTOR FUNCTION | 2005 |
|
RU2367667C2 |
| PREVENTING AND TREATING COMPLEMENT-CAUSED OCULAR PATHOLOGIES | 2008 |
|
RU2522976C2 |
| COMPOSITIONS FOR INHIBITION OF MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2636038C2 |
| IMPROVED ANTI-IGE-ANTIBODY (VARIANTS) AND METHOD FOR IMPROVING POLYPEPTIDES | 1998 |
|
RU2242515C2 |
| MONOCLONAL ANTIBODY DIRECTED AGAINST GNA33 PEPTIDE AND ITS APPLICATION | 2002 |
|
RU2355704C2 |
| ANTIBODIES AGAINST FACTOR D AND THEIR USE | 2018 |
|
RU2799044C2 |
| MOLECULAR MIMETICS OF MENINGOCOCCUS B EPITOPE THAT INDUCE PRODUCTION OF FUNCTIONALLY ACTIVE ANTIBODY | 2002 |
|
RU2322451C2 |
| METHOD FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2010 |
|
RU2600876C2 |
| MOLECULES WHICH BIND TO PSL PSEUDOMONAS, AND METHODS FOR USE THEREOF | 2012 |
|
RU2708977C2 |
